IL6 and lung cancer: From the above evidence, we could therefore comment that both IL-6 and IL-17, being pro-inflammatory, exert pro-tumor effects during later stages of tumor development, which therefore marks that these cytokines, being different, work synergistically to promote progressive events in lung cancer (59, 60).